First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial

Christian Marth, Richard G. Moore, Mariusz Bidziński, Vanda Salutari, Özden Altundağ, Maria Jesús Rubio, Tally Levy, Alison Stillie, Christof Vulsteke, Ralf Witteler, Kazuya Ariyoshi, Xiaohua Wu, Sophia Frentzas, André Mattar, Brian M. Slomovitz, Stephanie Lheureux, Xiaojun Chen, Kosei Hasegawa, Manuel Magallanes, Chel Hun Choi, Mariia Shalkova, Diego Lucas Kaen, Karen Cadoo, Lili Yao, Jodi McKenzie, Chinyere E. Okpara, Robin Meng, Robert Orlowski, Lucy Gilbert, Vicky Makker

Open source

DOI: 10.1016/j.ijgc.2025.102795
Published: 2026-01
Container: International Journal of Gynecological Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ijgc.2025.102795,
  title = {First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial},
  author = {Christian Marth and Richard G. Moore and Mariusz Bidziński and Vanda Salutari and Özden Altundağ and Maria Jesús Rubio and Tally Levy and Alison Stillie and Christof Vulsteke and Ralf Witteler and Kazuya Ariyoshi and Xiaohua Wu and Sophia Frentzas and André Mattar and Brian M. Slomovitz and Stephanie Lheureux and Xiaojun Chen and Kosei Hasegawa and Manuel Magallanes and Chel Hun Choi and Mariia Shalkova and Diego Lucas Kaen and Karen Cadoo and Lili Yao and Jodi McKenzie and Chinyere E. Okpara and Robin Meng and Robert Orlowski and Lucy Gilbert and Vicky Makker},
  year = {2026},
  journal = {International Journal of Gynecological Cancer},
  doi = {10.1016/j.ijgc.2025.102795},
  url = {https://doi.org/10.1016/j.ijgc.2025.102795}
}

RIS

TY  - JOUR
TI  - First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
AU  - Christian Marth
AU  - Richard G. Moore
AU  - Mariusz Bidziński
AU  - Vanda Salutari
AU  - Özden Altundağ
AU  - Maria Jesús Rubio
AU  - Tally Levy
AU  - Alison Stillie
AU  - Christof Vulsteke
AU  - Ralf Witteler
AU  - Kazuya Ariyoshi
AU  - Xiaohua Wu
AU  - Sophia Frentzas
AU  - André Mattar
AU  - Brian M. Slomovitz
AU  - Stephanie Lheureux
AU  - Xiaojun Chen
AU  - Kosei Hasegawa
AU  - Manuel Magallanes
AU  - Chel Hun Choi
AU  - Mariia Shalkova
AU  - Diego Lucas Kaen
AU  - Karen Cadoo
AU  - Lili Yao
AU  - Jodi McKenzie
AU  - Chinyere E. Okpara
AU  - Robin Meng
AU  - Robert Orlowski
AU  - Lucy Gilbert
AU  - Vicky Makker
PY  - 2026
JO  - International Journal of Gynecological Cancer
DO  - 10.1016/j.ijgc.2025.102795
UR  - https://doi.org/10.1016/j.ijgc.2025.102795
ER  -

APA

Marth, C., Moore, R. G., Bidziński, M., Salutari, V., Altundağ, Ö., Rubio, M. J., Levy, T., Stillie, A., Vulsteke, C., Witteler, R., Ariyoshi, K., Wu, X., Frentzas, S., Mattar, A., Slomovitz, B. M., Lheureux, S., Chen, X., Hasegawa, K., Magallanes, M., Choi, C. H., Shalkova, M., Kaen, D. L., Cadoo, K., Yao, L., McKenzie, J., Okpara, C. E., Meng, R., Orlowski, R., Gilbert, L., & Makker, V. (2026). First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial. International Journal of Gynecological Cancer. https://doi.org/10.1016/j.ijgc.2025.102795

Source records

crossref · retrieved 2026-09-26T14:14:17.501Z